Myeloma Australia's Medical and Scientific Advisory Group (MSAG) presents the article of the week. The article from Australia’s National Centre for...
News
Information About COVID-19 for Myeloma Patients
COVID-19, short for coronavirus disease 2019, is an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is...
Coronavirus in NZ: How to self-isolate – Kiwi diagnosed with cancer shares advice
A Kiwi diagnosed with cancer has shared advice on how to self-isolate while living with others and what precautions immunocompromised people should...
National Research Cancer Institute UK Confirms Benefit Molecular Profiling in Multiple Myeloma
ROTTERDAM, Netherlands and SAN DIEGO, March 17, 2020 /PRNewswire/ -- SkylineDx shares research showing that multiple myeloma (blood cancer) patients...
Myeloma and the Coronavirus
With rising community concern about the novel coronavirus or COVID-19, Myeloma Australia would like to provide the following information sheet...
New CAR T-cell Therapy Shows Early Promise Against Multiple Myeloma in Lab Study
A new CAR T-cell therapy for people with multiple myeloma has been successfully created and tested in cell-based experiments and a mouse model, a...
Organ responses with daratumumab therapy in previously treated AL amyloidosis
Immunoglobulin light chain amyloidosis (AL amyloidosis) involves deposition of abnormally folded light chains into a wide range of tissues causing...
Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy
Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will help to mitigate the interference of...
ALCYONE Update: Adding Daratumumab to VMP Improves Survival in Transplant-Ineligible Myeloma
In patients with newly diagnosed multiple myeloma (MM) who are ineligible for high-dose chemotherapy and transplantation, adding daratumumab to...
Cancer drug funding welcomed
Mark Wellington cherished the final years he spent with his wife after she was diagnosed with multiple myeloma. Now he wants Pharmac to make good on...
Myeloma NZ calls on Pharmac to make good on access deal
Myeloma New Zealand is today calling on Pharmac to make good on their proposal to widen access to blood cancer treatment lenalidomide (Revlimid)...
Pharmac to widen treatment access for myeloma – New Zealand’s second most common blood cancer
Media Release In a move welcomed by patient advocacy group Myeloma New Zealand, drug buying agency Pharmac has proposed to widen access to blood...